Assessment of Ultra-Early Administration of Sacubitril Valsartan to Improve Cardiac Remodeling in Patients With Acute Myocardial Infarction Following Primary PCI: Rational and Design of a Prospective, Multicenter, Randomized Controlled Trial

BACKGROUND: Despite coronary re-vascularization, the common complications of acute myocardial infarction (AMI), cardiac remodeling, and heart failure (HF), is increasing globally. Sacubitril valsartan (SV), an angiotensin receptor-neprilysin inhibitor (ARNI), has been previously demonstrated to impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhengwei, Fu, Guosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867085/
https://www.ncbi.nlm.nih.gov/pubmed/35222091
http://dx.doi.org/10.3389/fphys.2022.831212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867085/
https://www.ncbi.nlm.nih.gov/pubmed/35222091
http://dx.doi.org/10.3389/fphys.2022.831212

Ejemplares similares